A Proposed Framework to Monitor Daily Oral Antiretroviral Pre-Exposure Prophylaxis in the U.S
| Autor: | John Beltrami, Dawn K. Smith |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Program evaluation
medicine.medical_specialty Anti-HIV Agents Epidemiology Administration Oral HIV Infections Emtricitabine Pre-exposure prophylaxis Interim Humans Medicine Hepatitis business.industry Transmission (medicine) Public health Incidence (epidemiology) Health Plan Implementation Public Health Environmental and Occupational Health medicine.disease United States Primary Prevention Population Surveillance Family medicine business Program Evaluation medicine.drug |
| Zdroj: | American Journal of Preventive Medicine. 44:S141-S146 |
| ISSN: | 0749-3797 |
| Popis: | Safety and substantial efficacy have now been proven for daily antiretroviral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) in ombination with emtricitabine (FTC) for HIV-uninfected en who have sex with men (MSM) as well as heteroexual men and women. MSM and heterosexuals (who o not inject drugs) comprised 88% of the estimated new IV infections in the U.S. in 2009 and have evident need or additional prevention methods to substantially lower he incidence of HIV infections. A comprehensive national surveillance system exists for monitoring the diagnosis, treatment, and health effects of HIV infection. Periodic multi-city surveys monitor HIV risk and protective behaviors in key transmission risk groups. An additional national programmonitoring and evaluation system assesses elements of HIV testing, behavioral, and structural prevention prorams as delivered by community-based organizations nd health departments funded by the CDC. In the U.S., PrEP is already being prescribed by cliniians, sometimes consistent with interim guidance for its se and sometimes not. Anecdotal reports suggest that its use is increasing, but a system to monitor PrEP delivery, use, and health-related outcomes for HIVuninfected people receiving this antiretroviral preventive intervention in clinical settings has not yet been developed. An initial face-to-face consultation was held with public health, academic, and clinical experts experienced with HIV, STD, and hepatitis program evaluation and surveillance systems. During this meeting, a program logic model (Figure 1) was developed to guide consideration of elements that are important to monitor from national, state, and local perspectives. Additional telephone consultations followed to develop additional aspects of the framework described in this paper for monitoring the implementation, use, and impact of PrEP as an HIV prevention method in the U.S. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect